Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)

v3.22.2.2
Description of Business and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2021
Jun. 30, 2022
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)       $ 8,563    
Restructuring Charges, Total     $ 242 1,640 $ 142 $ 87
Payments for Restructuring       1,143    
Asset Impairment [Member]            
Restructuring Charges, Total     242      
Payments for Restructuring       554    
Employee Severance on Relocation of US Plant [Member]            
Restructuring Charges, Total   $ 200        
Payments for Restructuring       0    
Diagnostics and Genomics [Member]            
Restructuring Charges, Total       1,400    
Wilson Wolf Corporation [Member]            
Payments to Acquire Investments, Total $ 25,000     25,000    
Wilson Wolf Corporation [Member] | First Part of Forward Contract [Member]            
Forward Contract, Milestone, Annual Revenue Required     92,000 92,000    
Forward Contract, Milestone, Annual EBITDA     55,000 55,000    
Forward Contract Payment     $ 231,000 $ 231,000    
Noncontrolling Interest, Ownership Percentage by Parent     19.90% 19.90%    
Wilson Wolf Corporation [Member] | Second Part of Forward Contract [Member]            
Forward Contract, Milestone, Annual Revenue Required     $ 226,000 $ 226,000    
Forward Contract, Milestone, Annual EBITDA     136,000 136,000    
Forward Contract, Additional Investment     $ 1,000,000 $ 1,000,000    
Forward Contract, Milestone, Multiple for Total Expected Payments     4.4 4.4    
Changzhou Eminence Biotechnology [Member]            
Goodwill, Impairment Loss       $ 8,300    
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)   $ 8,600   8,600    
Inventory Write-down       900    
Asset Impairment Charges, Total       900    
Income (Loss) From Non-controlling Interest, Attributable to Parent       8,000    
Total Assets of Impaired Asset Group     $ 4,300 4,300    
Inventory of Impaired Asset Group     600 600    
Accounts Receivable of Impaired Asset Group     400 400    
Other Current Assets of Impaired Asset Group     100 100    
Current Liabilities of Impaired Asset Group     $ 4,500 $ 4,500    
Percentage of Interest in Tangible Assets in Liquidation Process     57.40% 57.40%    
Changzhou Eminence Biotechnology [Member] | Fixed Assets and Related Deposits [Member]            
Property, Plant and Equipment of Impaired Asset Group     $ 3,100 $ 3,100